Fosun Pharmaceutical Gets US FDA's Nod for Osteoporosis Drug
MT Newswires Live
Sep 02
Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196), through unit Shanghai Henlius Biotech, received approval from the US Food and Drug Administration for the biologics license applications of denosumab injection, a drug used to prevent osteoporosis and skeletal defects,
The approval is for the drug's two specifications, the Bildyos, with a 60 milligram/milliliter measurement, and Bilprevda, with a 120 mg/1.7 mL measurement.
The Chinese pharmaceutical company's Shanghai shares rose over 1% during morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.